Does antidepressive medication that antagonizes platelet 5-HT2A receptors reduce thromboembolic events in patients with depression and cardiovascular disease?
The 5-HT2A receptor signaling system may serve as a mechanistic link between depression and increased coronary events in cardiovascular patients, representing a potential therapeutic target.
Depression appears to be associated with an increased susceptibility for serotonin-mediated platelet activation. Upregulation and/or increased sensitivity of 5-HT2A/1B receptors and downregulated 5-HT transporter receptors in the periphery may contribute to increased risk of thromboembolic events in patients with depression and cardiovascular disease. Increased platelet reactivity based on a hyperreactive 5-HT2A receptor signaling system might be influenced by antidepressive medication that antagonizes platelet 5-HT2A receptors.
Schins et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: